194 related articles for article (PubMed ID: 22698960)
1. The effect of valsartan and nebivolol treatment on ADMA and pentraxin-3 levels in hypertensive patients.
Parlak A; Iyisoy A; Aydogan U; Cakir E; Saglam K
Med Hypotheses; 2012 Sep; 79(3):294-8. PubMed ID: 22698960
[TBL] [Abstract][Full Text] [Related]
2. The comparative effects of valsartan and amlodipine on vascular microinflammation in newly diagnosed hypertensive patients.
Unlu M; Karaman M; Ay SA; Balta S; Cakar M; Demirkol S; Celik T; Arslan E; Demirbas S; Turker T; Yaman H; Bulucu F; Sağlam K
Clin Exp Hypertens; 2013; 35(6):418-23. PubMed ID: 23148500
[TBL] [Abstract][Full Text] [Related]
3. Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients.
Pasini AF; Garbin U; Stranieri C; Boccioletti V; Mozzini C; Manfro S; Pasini A; Cominacini M; Cominacini L
Am J Hypertens; 2008 Nov; 21(11):1251-7. PubMed ID: 18772860
[TBL] [Abstract][Full Text] [Related]
4. Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation.
Yilmaz MI; Carrero JJ; Martín-Ventura JL; Sonmez A; Saglam M; Celik T; Yaman H; Yenicesu M; Eyileten T; Moreno JA; Egido J; Blanco-Colio LM
Clin J Am Soc Nephrol; 2010 Jul; 5(7):1174-81. PubMed ID: 20430947
[TBL] [Abstract][Full Text] [Related]
5. The effect of candesartan on pentraxin-3 plasma levels as marker of endothelial dysfunction in patients with essential arterial hypertension.
Buda V; Andor M; Cristescu C; Voicu M; Cochera F; Tuduce P; Petrescu L; Tomescu MC
Ir J Med Sci; 2017 Aug; 186(3):621-629. PubMed ID: 28220370
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study.
Giles TD; Weber MA; Basile J; Gradman AH; Bharucha DB; Chen W; Pattathil M;
Lancet; 2014 May; 383(9932):1889-98. PubMed ID: 24881993
[TBL] [Abstract][Full Text] [Related]
7. Effect of nebivolol and metoprolol treatments on serum asymmetric dimethylarginine levels in hypertensive patients with type 2 diabetes mellitus.
Oğuz A; Uzunlulu M; Yorulmaz E; Yalçin Y; Hekim N; Fici F
Anadolu Kardiyol Derg; 2007 Dec; 7(4):383-7. PubMed ID: 18065333
[TBL] [Abstract][Full Text] [Related]
8. [Comparative effects of nebivolol and valsartan on atrial electromechanical coupling in newly diagnosed stage 1 hypertensive patients].
Altun B; Acar G; Akçay A; Sökmen A; Kaya H; Köroğlu S
Turk Kardiyol Dern Ars; 2011 Oct; 39(7):563-7. PubMed ID: 21983766
[TBL] [Abstract][Full Text] [Related]
9. Nebivolol and valsartan as a fixed-dose combination for the treatment of hypertension.
Sander GE; Giles TD
Expert Opin Pharmacother; 2015 Apr; 16(5):763-70. PubMed ID: 25747524
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety of nebivolol and valsartan combination therapy in patients with hypertension: an open-label, single-arm, multicenter study.
Neutel JM; Giles TD; Punzi H; Weiss RJ; Li H; Finck A
J Am Soc Hypertens; 2014 Dec; 8(12):915-20. PubMed ID: 25492835
[TBL] [Abstract][Full Text] [Related]
11. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
[TBL] [Abstract][Full Text] [Related]
12. The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases.
Norata GD; Garlanda C; Catapano AL
Trends Cardiovasc Med; 2010 Feb; 20(2):35-40. PubMed ID: 20656213
[TBL] [Abstract][Full Text] [Related]
13. Nebivolol therapy improves endothelial function and increases exercise tolerance in patients with cardiac syndrome X.
Sen N; Tavil Y; Erdamar H; Yazici HU; Cakir E; Akgül EO; Bilgi C; Erbil MK; Poyraz F; Okyay K; Turfan M; Cemri M
Anadolu Kardiyol Derg; 2009 Oct; 9(5):371-9. PubMed ID: 19819787
[TBL] [Abstract][Full Text] [Related]
14. Vascular effects of nebivolol added to hydrochlorothiazide in African Americans with hypertension and echocardiographic evidence of diastolic dysfunction: the NASAA study.
Khan BV; Rahman ST; Haque T; Merchant N; Bhaheetharan S; Harris J; Umar K; Wahi J; Ferdinand KC
J Cardiovasc Pharmacol Ther; 2012 Sep; 17(3):291-7. PubMed ID: 22388001
[TBL] [Abstract][Full Text] [Related]
15. The effect of nebivolol on asymmetric dimethylarginine system in spontaneously hypertension rats.
Wang Y; Zhang M; Liu Y; Liu Y; Chen M
Vascul Pharmacol; 2011; 54(1-2):36-43. PubMed ID: 21167314
[TBL] [Abstract][Full Text] [Related]
16. Nebivolol and metoprolol: long-term effects on inflammation and oxidative stress in essential hypertension.
Serg M; Kampus P; Kals J; Zagura M; Zilmer M; Zilmer K; Kullisaar T; Eha J
Scand J Clin Lab Invest; 2012 Sep; 72(5):427-32. PubMed ID: 22708640
[TBL] [Abstract][Full Text] [Related]
17. The long pentraxin PTX3 in vascular pathology.
Mantovani A; Garlanda C; Bottazzi B; Peri G; Doni A; Martinez de la Torre Y; Latini R
Vascul Pharmacol; 2006 Nov; 45(5):326-30. PubMed ID: 17023219
[TBL] [Abstract][Full Text] [Related]
18. The Effect of Corrected Inflammation, Oxidative Stress and Endothelial Dysfunction on Fmd Levels in Patients with Selected Chronic Diseases: A Quasi-Experimental Study.
Yilmaz MI; Romano M; Basarali MK; Elzagallaai A; Karaman M; Demir Z; Demir MF; Akcay F; Seyrek M; Haksever N; Piskin D; Cimaz R; Rieder MJ; Demirkaya E
Sci Rep; 2020 Jun; 10(1):9018. PubMed ID: 32488098
[TBL] [Abstract][Full Text] [Related]
19. Long pentraxin 3 (PTX3) in the light of its structure, mechanism of action and clinical implications.
Cieślik P; Hrycek A
Autoimmunity; 2012 Mar; 45(2):119-28. PubMed ID: 21988562
[TBL] [Abstract][Full Text] [Related]
20. Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan.
Yilmaz MI; Saglam M; Sonmez A; Caglar K; Cakir E; Kurt Y; Eyileten T; Tasar M; Acikel C; Oguz Y; Vural A; Yenicesu M
Blood Purif; 2007; 25(4):327-35. PubMed ID: 17709915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
